Showing 371-380 of 3150 results for "".
What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thDermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneEnsuring Excellent Care Across LGBTQ and Sexual Minority Patients
https://practicaldermatology.com/topics/practice-management/ensuring-excellent-care-across-lgbtq-and-sexual-minority-patients/20077/The session on LGBTQ and sexual gender minority health covered a range of topics including both clinical care as well as terminology, structures, and framework. Klint Peebles, MD talks about the importance of providing excellent dermatologic care as patients face disparities and challenges in accessScientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancAn Excellent Networking Opportunity: DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/an-excellent-networking-opportunity-derm2021/19963/From opportunities to connect and network with other NPs and PAs to going to sessions presented by some of her favorite dermatologists, such as Ted Rosen, MD, to learn about what’s in the pipeline and coming to market soon, Leigh Ann Pansch, MSN, FNP-BC, DCNP is excited to attend the DERM2021 NP/PAThe Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.The Time is Now: Dermatology and Climate Change
https://practicaldermatology.com/topics/practice-management/the-time-is-now-dermatology-and-climate-change/19930/How are global warming and associated changes in weather affecting the presentation of skin diseases? And what opportunities do dermatologists have to help turn the tide of global warning? Misha Rosenbach, MD reviews the science and touches on opportunities for change.